Insight Molecular Diagnostics (IMDX) Profit After Tax (2015 - 2026)

Insight Molecular Diagnostics has disclosed Profit After Tax across 12 years of filings, most recently posting -$4.3 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$4.3 million, up 35.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$47.8 million (up 17.81% YoY), and the FY2025 annual result was -$50.2 million, up 17.21% from the prior year.
• Profit After Tax came in at -$4.3 million for Q1 2026 at Insight Molecular Diagnostics, up from -$23.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $6.0 million in Q1 2023 to a low of -$45.0 million in Q4 2022.
• The 5-year median for Profit After Tax is -$9.3 million (2022), against an average of -$12.5 million.
• Across the five-year window, Profit After Tax soared 157.9% in 2023 and slumped 253.2% in 2024, its largest moves.
• Insight Molecular Diagnostics' Profit After Tax stood at -$45.0 million in 2022, then surged by 64.44% to -$16.0 million in 2023, then slumped by 109.55% to -$33.5 million in 2024, then jumped by 31.5% to -$23.0 million in 2025, then surged by 81.31% to -$4.3 million in 2026.
• The last three Profit After Tax figures came in at -$4.3 million (Q1 2026), -$23.0 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.